Can kidney size predict disease progression in ADPKD? new study investigates
NCT ID NCT06193616
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This observational study reviews medical records from 70 adults with advanced autosomal dominant polycystic kidney disease (ADPKD) who are already taking the drug octreotide LAR. Researchers want to see if baseline kidney volume and other factors can predict how quickly kidney function declines over time. The goal is to better understand the disease course, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- octreotide LAR
- What this could lead to
- If successful, this study could help doctors better predict which patients with advanced ADPKD will have faster kidney decline, potentially guiding treatment decisions.
- What could go wrong
- This is a small, retrospective, observational study—it cannot prove cause and effect. Results may not apply to all patients, and no new treatment is being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Dec 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with ADPKD who have undergone chronic treatment with octreotide LAR (in accordance with Law N. 648 of December23, 1996), suffering from stage IV CKD and who have been regularly followed, through serial measurements of GFR and TKV and clinical examinations, at the outpatient clinic of the Nephrology Unit at the ASST Papa Giovanni XXIII in Bergamo, Italy.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ADPKD patients with criteria for the prescription of octreotide LAR according to Law n. 648, 23 December 1996: ≥ 18 year-old; Clinical and instrumental diagnosis of ADPKD; Estimated GFR (MDRD): ≥ 15 ml/min/1.73m2 and \<30 ml/min/1.73m2. * Written informed consent to participate in the observational study and to the use of recorded data for research purposes. * Availability of an adequate (for quantitative volumetric analyses) non-contrast enhanced Computed Tomography (CT) scan acquired before starting octreotide-LAR therapy. * Follow-up of at least six months (eg. up to the first post-treatment GFR evaluation from the start of chronic octreotide LAR treatment). Exclusion Criteria: * Legal incapacity or limited legal capacity. * Contraindications to the prescription of octreotide LAR according to Law n. 648, 23 December 1996.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autosomal dominant polycystic kidney are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASST HPG23 - Unità di Nefrologia
Bergamo, BG, 24100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.